NEWSROOM
October 4, 2021
Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology
September 23, 2021
Agreement adds cutting-edge innovation to Galderma’s aesthetic injectable portfolio, the aesthetic industry’s broadest i
October 4, 2021
Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021
September 9, 2021
RESTYLANE® EYELIGHT™ to launch as new targeted treatment solution for under-eye shadows
October 4, 2021
Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe
June 11, 2021
Data supporting the positive decision demonstrated that patients treated with Alluzience® for wrinkles had a rapid onset of e
October 4, 2021
How Galderma's Environmental, Social and corporate Governance approach guides its roadmap for sustainable growth
May 19, 2021
Cécile Dussart discusses ESG being an integral part of Galderma's business
October 4, 2021
RESTYLANE®, the original stabilized hyaluronic acid filler, celebrates 25 years of unmatched achievement
September 30, 2021
The unsurpassed NASHA™ technology, which is still used today as the benchmark for fillers, was pioneered by Galderma
March 23, 2021
Galderma continues global growth ambition with Sculptra® (injectable poly-L-lactic acid) re-launch in Europe
March 4, 2021
Updated administration protocol means Sculptra® offers the fastest reconstitution of any injectable PLLA available in Europe.
March 23, 2021
Galderma receives FDA approval for Restylane® Defyne for chin augmentation
February 4, 2021
Represents second approved indication for Restylane Defyne in U.S.
November 19, 2020
Galderma launches Dysport® in China for treatment of glabellar lines
November 18, 2020
Dysport® is a prescription injection for temporary improvement in the look of moderate to severe glabellar lines.
November 19, 2020
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
November 17, 2020
Phase 2 study on the impact of dose escalation on the duration of effect, efficacy and safety of a single dose of Dysport®